In Vitro Maturation (IVM) of Human Oocytes

Weill Medical College of Cornell University2 enrolled

Overview

The objectives of this study are to evaluate the clinical efficacy of Natural in vitro Fertilization and in vitro maturation.

Collection of one mature egg from a follicle in the ovary without gonadotropin medications (natural cycle IVF) results in low pregnancy rates. One way to improve natural cycle IVF is to combine this procedure with the removal of immature eggs from the ovary and mature these eggs in the laboratory ( in vitro maturation-IVM). The in vitro mature eggs are fertilized and the resultant embryos are cultured using conventional IVF techniques.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Infertility

Interventions

in vitro maturationPROCEDURE

Maturation of immature oocytes in the laboratory following oocyte retrieval

Polar Body Biopsy with preimplantation genetic screeningPROCEDURE

Polar body biopsy is performed on the day that the oocyte is retrieved. Microarray analysis will will be performed and compared with FISH and microarray analysis of day 3 or day 5 biopsy.

Eligibility

Sex: FEMALEMin age: 25 YearsMax age: 42 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Each subject must be female. 2. Each subject must have an indication for COH and IVF with or without ICSI. 3. Each subject must be willing and able to provide written informed consent for the trial 4. Each subject must be 25 to ≤42 years of age at the time of signing informed consent. 5. Each subject must have a normal cervical smear result (no atypical or abnormal cells, or in case of atypical squamous or glandular cells, no signs of malignancy; corresponding to Papanicolaou \[PAP\] I or II) obtained within 12 months prior to signing informed consent must be available Exclusion Criteria: 1. Subject with premature ovarian failure 2. Subject with endocrine abnormalities such as hyperprolactinaemia or thyroid dysfunction 3. Subject with malformation or absence of uterus 4. Subject has tested positive for Human Immunodeficiency Virus (HIV) or Hepatitis B (by local laboratory; results obtained within 1 year prior to signing ICF are considered valid). 5. Subject with contraindication or allergy/hypersensitivity to hCG, estrogen and progesterone

Locations (1)

Center for Reproductive Medicine- Weill Cornell Medical College

New York, New York, United States

Outcomes

Primary Outcomes

number of oocytes retrieved and embryos generated

Time frame: 1 year

Secondary Outcomes

live birth rate

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.